News

Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal
Avalon’s Andrew Briggs Conducted Work on the Excess Mortality Attributable to COVID-19 Featured in the Wall Street Journal 860 484 Avalon Health Economics LLC

The Wall Street Journal recently covered the work that Avalon’s Andrew Briggs conducted on the excess mortality attributable to COVID-19. Briggs put the U.S. average at almost 14 years lost and the U.K. average at almost 11 years.

read more

Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department
Cost Impact Model of a Novel Multi-mRNA Host Response Assay for Diagnosis and Risk Assessment of Acute Respiratory Tract Infections and Sepsis in the Emergency Department 860 484 Avalon Health Economics LLC

The Avalon team helped Inflammatix, Inc., develop economic evidence for HostDx Sepsis test for the diagnosis of acute infections. A newly released publication describes a cost impact model comparing the cost of standard of care versus the use of HostDx Sepsis in two hypothetical arms with 1000 patients presenting with symptoms of ARTI in the…

read more

Electronic Medical Records: Potential Issues in Litigation and Biomedical Research
Electronic Medical Records: Potential Issues in Litigation and Biomedical Research 860 484 Avalon Health Economics LLC

In this blog entry we explore some of the potentially important issues surrounding the role of EMRs in litigation, where the discovery of medical documents and records increasing involves digitally stored data.[1-4]

read more

Estimating QALY Losses Associated With Deaths in Hospital (COVID-19)
Estimating QALY Losses Associated With Deaths in Hospital (COVID-19) 860 484 Avalon Health Economics LLC

Avalon Director Andrew Briggs, DPhil, addresses the issue of potential losses in quality-adjusted life years (QALYs) associated with COVID-19.

read more

COVID-19: Update on Epidemiology & Costs
COVID-19: Update on Epidemiology & Costs 860 484 Avalon Health Economics LLC

We define epidemiology broadly, including an up-to-date review of the key published medical literature on COVID-19. Following that, our discussion of costs focuses in part on the direct medical costs (which probably for good reasons has been relatively under-reported) and in part on the broader costs to the economy.

read more

Distinguishing Between Viral and Bacterial Respiratory Infections
Distinguishing Between Viral and Bacterial Respiratory Infections 860 484 Avalon Health Economics LLC

Avalon researchers published important research on distinguishing between viral and bacterial respiratory infections, a topic that is of great importance given the COVID-19 pandemic. Check out the study at: https://www.tandfonline.com/doi/full/10.1080/13696998.2020.1736872

read more

The Coronavirus: How Bad is it, Really?
The Coronavirus: How Bad is it, Really? 860 484 Avalon Health Economics LLC

Within a few months we’ve gone from worrying about holiday shopping to worrying about global pandemics and watching the world shut down around us. It started with news from China on the rapid spread of an insidious virus initially called a coronavirus.[1] Once the virus was better understood it became known as COVID-19. The disease…

read more

Avalon Health Economics Will Be At ISPOR Copenhagen 2019
Avalon Health Economics Will Be At ISPOR Copenhagen 2019 860 484 Avalon Health Economics LLC

Avalon Health Economics will be at ISPOR Copenhagen November 2nd-6th. Let us know if you will be there and want to set up a meeting! For more information, please visit the ISPOR website.

read more

New HEOR Publication: Monitoring Technology for Seniors
New HEOR Publication: Monitoring Technology for Seniors 1024 1024 Avalon Health Economics LLC

Economic evaluation of passive monitoring technology for seniors 2019 By John E. Schneider,  Jacie Cooper. Cara Scheibling, and Anjani Parikh Abstract: By 2050, the global population of persons over the age of 60 is expected to be between 1.5 and 2 billion [1, 2]. Moreover, the proportion of individuals over the age of 80 is simultaneously and…

read more

Avalon & Oberender Enter a New Collaboration
Avalon & Oberender Enter a New Collaboration 860 484 Avalon Health Economics LLC

    Avalon Health Economics has entered into a collaborative agreement with Oberender, a leading global healthcare management consultancy based in Germany.  The agreement allows Avalon and Oberender to collaborate in a variety of ways, offering Avalon’s U.S. clients access to European market access, technology assessment, and management consulting, and offering Oberender added reach into…

read more
Start Typing
Loading...